表紙
市場調查報告書
商品編碼
915217

動物疼痛管理的全球市場

Veterinary Pain Management Market by Product and Geography - Forecast and Analysis 2020-2024

出版日期: | 出版商: TechNavio (Infiniti Research Ltd.) | 英文 145 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球動物疼痛管理市場在預測期間內預計將以約9%的年複合成長率成長。已開發國家的獸醫師數的增加,動物的健康及福利的認識提高,伴隨動物疼痛的慢性疾病的罹患率高,動物的醫療支出增加伴隨的寵物保險的需求高漲等促進這個市場成長。

本報告提供全球動物疼痛管理市場調查,市場概要,各產品、各地區的市場規模的變化與預測,市場成長要素及課題分析,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 摘要整理

第2章 報告範圍

第3章 市場情形

  • 市場生態系統
  • 市場特性
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模
  • 市場規模的變化與預測

第5章 波特的五力分析

  • 買方議價能力
  • 供給企業談判力
  • 新加入業者的威脅
  • 替代品的威脅
  • 競爭企業間的敵對關係
  • 市場情況

第6章 市場區隔:各產品

  • 市場區隔:各產品
  • 市場比較:各產品
  • 醫藥品
  • 醫療設備
  • 市場機會:各產品

第7章 客戶形勢

第8章 地區形勢

  • 市場區隔:各地區
  • 市場比較:各地區
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

  • 飼養的寵物增加
  • 非傳統及非藥物治療的偏好高漲
  • 動物的醫療費增加伴隨的寵物保險的需求增加

第12章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭方案

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Cadila Healthcare Ltd.
  • Chanelle Pharma Group
  • 第一三共
  • Dechra Pharmaceuticals Plc
  • Elanco Animal Health Inc.
  • Merck & Co. Inc.
  • Norbrook Holdings Ltd.
  • Zoetis Inc.

第14章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第15章 關於Technavio

目錄
Product Code: IRTNTR40044

About this market

Technavio's veterinary pain management market analysis considers sales from both pain management drugs and pain management devices. Our report also provides a detailed analysis of the market in Asia, Europe, North America, and ROW. In 2019, the drugs segment had a significant market share, and this trend is expected to continue over the forecast period. With the high prevalence of painful and inflammatory diseases, the drugs segment will maintain its market position. Also, our global veterinary pain management market report looks at factors such as growth in the number of veterinarians and their income in developed countries and the growing awareness about animal health and welfare. However, the high costs associated with pet care, side effects associated with veterinary therapeutics, and stringent regulatory approval process for pain management drugs may hamper the growth of the veterinary pain management industry over the forecast period.

Overview

The high prevalence of painful and inflammatory diseases

The rising obesity in pets is one of the significant risk factors for several chronic conditions. One of the common chronic conditions is osteoarthritis. This creates the need for treatments which includes NSAIDs, adjunctive pain medications, and joint supplements. The high prevalence of painful and inflammatory diseases in animals will increase the prescription of several pharmaceuticals. This will lead to the expansion of the global veterinary pain management market at a CAGR of almost 9% during the forecast period.

Rising demand for pet insurance with growing animal health expenditure

With the rising cost of animal healthcare, people are relying on pet insurance to reduce the direct financial burden. Pet insurance providers offer reimbursement-based programs. Such policies majorly cover accidental injuries, prescription drugs, and surgical procedures. This will increase marketing efforts by pet insurance companies resulting in veterinary pain management market growth.

For the detailed list of factors that will drive the global veterinary pain management market during the forecast period 2020-2024, view our report.

Competitive Landscape

With the presence of several major players, the global veterinary pain management market is fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading veterinary pain management market vendors, that include Bayer AG, Boehringer Ingelheim International GmbH, Cadila Healthcare Ltd., Chanelle Pharma Group, Daiichi Sankyo Co. Ltd., Dechra Pharmaceuticals Plc, Elanco Animal Health Inc., Merck & Co. Inc., Norbrook Holdings Ltd., and Zoetis Inc.

Also, the veterinary pain management market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2019
  • Market size and forecast 2019-2024

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Drugs - Market size and forecast 2019-2024
  • Devices - Market size and forecast 2019-2024
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Growth in adoption of companion animals
  • Increasing preference for non-conventional and non-pharmaceutical
  • treatments
  • Rising demand for pet insurance with growing animal health expenditure

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Cadila Healthcare Ltd.
  • Chanelle Pharma Group
  • Daiichi Sankyo Co. Ltd.
  • Dechra Pharmaceuticals Plc
  • Elanco Animal Health Inc.
  • Merck & Co. Inc.
  • Norbrook Holdings Ltd.
  • Zoetis Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

LIST OF EXHIBITS:

  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2019
  • Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
  • Exhibit 10: Five forces analysis 2019
  • Exhibit 11: Five forces analysis 2024
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2019
  • Exhibit 18: Product - Market share 2019-2024 (%)
  • Exhibit 19: Comparison by product
  • Exhibit 20: Drugs - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 21: Drugs - Year-over-year growth 2020-2024 (%)
  • Exhibit 22: Devices - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 23: Devices - Year-over-year growth 2020-2024 (%)
  • Exhibit 24: Market opportunity by product
  • Exhibit 25: Customer landscape
  • Exhibit 26: Market share by geography 2019-2024 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: North America - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 29: North America - Year-over-year growth 2020-2024 (%)
  • Exhibit 30: Top 3 countries in North America
  • Exhibit 31: Europe - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 32: Europe - Year-over-year growth 2020-2024 (%)
  • Exhibit 33: Top 3 countries in Europe
  • Exhibit 34: Asia - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 35: Asia - Year-over-year growth 2020-2024 (%)
  • Exhibit 36: Top 3 countries in Asia
  • Exhibit 37: ROW - Market size and forecast 2019-2024 ($ millions)
  • Exhibit 38: ROW - Year-over-year growth 2020-2024 (%)
  • Exhibit 39: Top 3 countries in ROW
  • Exhibit 40: Key leading countries
  • Exhibit 41: Market opportunity
  • Exhibit 42: Impact of drivers and challenges
  • Exhibit 43: Vendor landscape
  • Exhibit 44: Landscape disruption
  • Exhibit 45: Vendors covered
  • Exhibit 46: Vendor classification
  • Exhibit 47: Market positioning of vendors
  • Exhibit 48: Bayer AG - Vendor overview
  • Exhibit 49: Bayer AG - Business segments
  • Exhibit 50: Bayer AG - Organizational developments
  • Exhibit 51: Bayer AG - Geographic focus
  • Exhibit 52: Bayer AG - Segment focus
  • Exhibit 53: Bayer AG - Key offerings
  • Exhibit 54: Bayer AG - Key customers
  • Exhibit 55: Boehringer Ingelheim International GmbH - Vendor overview
  • Exhibit 56: Boehringer Ingelheim International GmbH - Product segments
  • Exhibit 57: Boehringer Ingelheim International GmbH - Organizational developments
  • Exhibit 58: Boehringer Ingelheim International GmbH - Geographic focus
  • Exhibit 59: Boehringer Ingelheim International GmbH - Segment focus
  • Exhibit 60: Boehringer Ingelheim International GmbH - Key offerings
  • Exhibit 61: Boehringer Ingelheim International GmbH - Key customers
  • Exhibit 62: Cadila Healthcare Ltd. - Vendor overview
  • Exhibit 63: Cadila Healthcare Ltd. - Business segments
  • Exhibit 64: Cadila Healthcare Ltd. - Organizational developments
  • Exhibit 65: Cadila Healthcare Ltd. - Geographic focus
  • Exhibit 66: Cadila Healthcare Ltd. - Key offerings
  • Exhibit 67: Cadila Healthcare Ltd. - Key customers
  • Exhibit 68: Chanelle Pharma Group - Vendor overview
  • Exhibit 69: Chanelle Pharma Group - Business segments
  • Exhibit 70: Chanelle Pharma Group - Organizational developments
  • Exhibit 71: Chanelle Pharma Group - Key offerings
  • Exhibit 72: Chanelle Pharma Group - Key customers
  • Exhibit 73: Daiichi Sankyo Co. Ltd. - Vendor overview
  • Exhibit 74: Daiichi Sankyo Co. Ltd. - Business segments
  • Exhibit 75: Daiichi Sankyo Co. Ltd. - Organizational developments
  • Exhibit 76: Daiichi Sankyo Co. Ltd. - Geographic focus
  • Exhibit 77: Daiichi Sankyo Co. Ltd. - Key offerings
  • Exhibit 78: Daiichi Sankyo Co. Ltd. - Key customers
  • Exhibit 79: Dechra Pharmaceuticals Plc - Vendor overview
  • Exhibit 80: Dechra Pharmaceuticals Plc - Product segments
  • Exhibit 81: Dechra Pharmaceuticals Plc - Organizational developments
  • Exhibit 82: Dechra Pharmaceuticals Plc - Geographic focus
  • Exhibit 83: Dechra Pharmaceuticals Plc - Segment focus
  • Exhibit 84: Dechra Pharmaceuticals Plc - Key offerings
  • Exhibit 85: Dechra Pharmaceuticals Plc - Key customers
  • Exhibit 86: Elanco Animal Health Inc. - Vendor overview
  • Exhibit 87: Elanco Animal Health Inc. - Product segments
  • Exhibit 88: Elanco Animal Health Inc. - Organizational developments
  • Exhibit 89: Elanco Animal Health Inc. - Geographic focus
  • Exhibit 90: Elanco Animal Health Inc. - Segment focus
  • Exhibit 91: Elanco Animal Health Inc. - Key offerings
  • Exhibit 92: Elanco Animal Health Inc. - Key customers
  • Exhibit 93: Merck & Co. Inc. - Vendor overview
  • Exhibit 94: Merck & Co. Inc. - Business segments
  • Exhibit 95: Merck & Co. Inc. - Organizational developments
  • Exhibit 96: Merck & Co. Inc. - Geographic focus
  • Exhibit 97: Merck & Co. Inc. - Segment focus
  • Exhibit 98: Merck & Co. Inc. - Key offerings
  • Exhibit 99: Merck & Co. Inc. - Key customers
  • Exhibit 100: Norbrook Holdings Ltd. - Vendor overview
  • Exhibit 101: Norbrook Holdings Ltd. - Product segments
  • Exhibit 102: Norbrook Holdings Ltd. - Organizational developments
  • Exhibit 103: Norbrook Holdings Ltd. - Geographic focus
  • Exhibit 104: Norbrook Holdings Ltd. - Segment focus
  • Exhibit 105: Norbrook Holdings Ltd. - Key offerings
  • Exhibit 106: Norbrook Holdings Ltd. - Key customers
  • Exhibit 107: Zoetis Inc. - Vendor overview
  • Exhibit 108: Zoetis Inc. - Product segments
  • Exhibit 109: Zoetis Inc. - Organizational developments
  • Exhibit 110: Zoetis Inc. - Geographic focus
  • Exhibit 111: Zoetis Inc. - Segment focus
  • Exhibit 112: Zoetis Inc. - Key offerings
  • Exhibit 113: Zoetis Inc. - Key customers
  • Exhibit 114: Validation techniques employed for market sizing
  • Exhibit 115: Definition of market positioning of vendors